Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) announced that it relocates the U.S. subsidiary ONO PHARMA USA, Inc. (President/CEO: Kunihiko Ito) to Cambridge, Massachusetts, and opens a new office on April 27, 2021 (EST).

　This relocation to the new office is intended to establish a framework that enables us to conduct clinical development and application for approval in anticipation of our own sales in the U.S. in the future, as well as to accelerate drug discovery alliance and licensing activities.

　Cambridge, Massachusetts is a major center for many of the world's leading universities and research institutions, including the Massachusetts Institute of Technology (MIT) and Harvard University, as well as numerous global pharmaceutical and bio-venture companies, and there are many opportunities to acquire excellent talent. ONO believes this relocation positions us to drive our global activity in clinical development and to accelerate globalization of our business toward "the realization of our own marketing activities in the U.S. and Europe" which is one of our corporate growth strategies.

【Outline of the New Office】

Building name	：Riverfront Office Park
Address	：Riverfront Office Park, One Main Street, Suite 1050, Cambridge, Massachusetts, 02142, USA